Affimed (AFMD) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

AFMD Stock Forecast


Affimed stock forecast is as follows: an average price target of $7.50 (represents a 129.36% upside from AFMD’s last price of $3.27) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

AFMD Price Target


The average price target for Affimed (AFMD) is $7.50 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $5.00. This represents a potential 129.36% upside from AFMD's last price of $3.27.

AFMD Analyst Ratings


Buy

According to 5 Wall Street analysts, Affimed's rating consensus is 'Buy'. The analyst rating breakdown for AFMD stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Affimed Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 01, 2024Bradley CaninoStifel Nicolaus$5.00$5.30-5.66%52.91%
Apr 01, 2024Swayampakula RamakanthH.C. Wainwright$10.00$5.3088.68%205.81%
Row per page
Go to

The latest Affimed stock forecast, released on Apr 01, 2024 by Bradley Canino from Stifel Nicolaus, set a price target of $5.00, which represents a -5.66% decrease from the stock price at the time of the forecast ($5.30), and a 52.91% increase from AFMD last price ($3.27).

Affimed Price Target by Period


1M3M12M
# Anlaysts--2
Avg Price Target--$7.50
Last Closing Price$3.27$3.27$3.27
Upside/Downside-100.00%-100.00%129.36%

In the current month, the average price target of Affimed stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Affimed's last price of $3.27. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Jun 12, 2024LaidlawBuyBuyHold
Apr 01, 2024H.C. WainwrightBuyBuyHold
Dec 12, 2022H.C. Wainwright-BuyInitialise
Oct 11, 2022Stifel Nicolaus-PositiveDowngrade
Mar 31, 2022Piper Sandler-OverweightInitialise
Feb 23, 2022Cantor Fitzgerald-OverweightInitialise
Row per page
Go to

Affimed's last stock rating was published by Laidlaw on Jun 12, 2024. The company gave AFMD a "Buy" rating, the same as its previous rate.

Affimed Financial Forecast


Affimed Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue---------------$4.51M$11.16M$14.89M$7.30M$8.01M$10.34M$8.66M$9.71M$11.66M$9.75M$10.54M$2.93M$5.13M$3.93M$2.10M
Avg Forecast$151.48K$151.73K$151.98K$152.23K$362.75K$362.75K$362.75K$362.75K$1.63M$1.67M$1.16M$458.57K$1.66M$1.93M$4.65M$6.16M$6.92M$6.29M$8.83M$10.31M$8.98M$9.59M$9.01M$10.63M$16.63M$8.79M$5.20M$5.47M$3.09M$3.71M
High Forecast$151.48K$151.73K$151.98K$152.23K$362.75K$362.75K$362.75K$362.75K$1.63M$2.67M$1.16M$458.57K$2.62M$1.93M$4.65M$6.16M$6.92M$6.29M$8.83M$10.31M$8.98M$9.59M$9.01M$10.63M$16.63M$8.79M$5.20M$5.47M$3.09M$3.71M
Low Forecast$151.48K$151.73K$151.98K$152.23K$362.75K$362.75K$362.75K$362.75K$1.63M$663.31K$1.16M$458.57K$643.08K$1.93M$4.65M$6.16M$6.92M$6.29M$8.83M$10.31M$8.98M$9.59M$9.01M$10.63M$16.63M$8.79M$5.20M$5.47M$3.09M$3.71M
# Analysts111111112322522211112222118812712
Surprise %---------------0.73%1.61%2.37%0.83%0.78%1.15%0.90%1.08%1.10%0.59%1.20%0.56%0.94%1.27%0.57%

Affimed's average Quarter revenue forecast for Jun 23 based on 2 analysts is $4.65M, with a low forecast of $4.65M, and a high forecast of $4.65M. AFMD's average Quarter revenue forecast represents a 3.18% increase compared to the company's last Quarter revenue of $4.51M (Mar 23).

Affimed EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts111111112322522211112222118812712
EBITDA---------------$-30.66M$-27.85M$-18.73M$-21.33M$-16.85M$-22.51M$-16.56M$-18.24M$1.83M$-14.66M$-5.65M$-11.90M$-7.95M$-12.64M$-10.55M
Avg Forecast$-151.48K$-151.73K$-151.98K$-152.23K$-362.75K$-362.75K$-362.75K$-362.75K$-1.63M$-1.67M$-1.16M$-458.57K$-1.66M$-1.93M$-4.65M$-6.16M$-6.92M$-6.29M$-8.83M$-10.31M$-8.98M$-9.59M$-9.01M$3.71M$-16.63M$-8.79M$-5.20M$-7.95M$-3.09M$-3.71M
High Forecast$-151.48K$-151.73K$-151.98K$-152.23K$-362.75K$-362.75K$-362.75K$-362.75K$-1.63M$-663.31K$-1.16M$-458.57K$-643.08K$-1.93M$-4.65M$-6.16M$-6.92M$-6.29M$-8.83M$-10.31M$-8.98M$-9.59M$-9.01M$4.45M$-16.63M$-8.79M$-5.20M$-6.36M$-3.09M$-3.71M
Low Forecast$-151.48K$-151.73K$-151.98K$-152.23K$-362.75K$-362.75K$-362.75K$-362.75K$-1.63M$-2.67M$-1.16M$-458.57K$-2.62M$-1.93M$-4.65M$-6.16M$-6.92M$-6.29M$-8.83M$-10.31M$-8.98M$-9.59M$-9.01M$2.96M$-16.63M$-8.79M$-5.20M$-9.53M$-3.09M$-3.71M
Surprise %---------------4.97%4.03%2.98%2.42%1.63%2.51%1.73%2.02%0.49%0.88%0.64%2.29%1.00%4.09%2.85%

2 analysts predict AFMD's average Quarter EBITDA for Jun 21 to be $-9.01M, with a high of $-9.01M and a low of $-9.01M. This is -592.55% lower than Affimed's previous annual EBITDA (Mar 21) of $1.83M.

Affimed Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts111111112322522211112222118812712
Net Income---------------$-31.98M$-36.73M$-13.77M$-17.16M$-16.66M$-23.27M$-17.09M$-18.75M$1.41M$-14.87M$-5.97M$-12.24M$-8.29M$-12.99M$-10.88M
Avg Forecast$-14.58M$-14.61M$-12.70M$-12.73M$-11.04M$-9.45M$-8.14M$-8.71M$-10.52M$-14.08M$-14.80M$-23.76M$-23.64M$-28.26M$-28.60M$-29.22M$-29.11M$-26.55M$-25.57M$-26.95M$-24.51M$-21.42M$-13.11M$2.86M$-2.27M$-12.58M$-20.23M$-8.29M$-27.32M$-27.44M
High Forecast$-14.58M$-14.61M$-12.70M$-12.73M$-11.04M$-9.45M$-8.14M$-8.71M$-10.52M$-13.71M$-14.80M$-23.76M$-17.84M$-28.26M$-28.60M$-29.22M$-29.11M$-26.55M$-25.57M$-26.95M$-24.51M$-21.42M$-13.11M$3.43M$-2.27M$-12.58M$-20.23M$-6.63M$-27.32M$-27.44M
Low Forecast$-14.58M$-14.61M$-12.70M$-12.73M$-11.04M$-9.45M$-8.14M$-8.71M$-10.52M$-14.70M$-14.80M$-23.76M$-30.63M$-28.26M$-28.60M$-29.22M$-29.11M$-26.55M$-25.57M$-26.95M$-24.51M$-21.42M$-13.11M$2.29M$-2.27M$-12.58M$-20.23M$-9.95M$-27.32M$-27.44M
Surprise %---------------1.09%1.26%0.52%0.67%0.62%0.95%0.80%1.43%0.49%6.54%0.47%0.61%1.00%0.48%0.40%

Affimed's average Quarter net income forecast for Jun 21 is $-13.11M, with a range of $-13.11M to $-13.11M. AFMD's average Quarter net income forecast represents a -1028.18% decrease compared to the company's last Quarter net income of $1.41M (Mar 21).

Affimed SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts111111112322522211112222118812712
SG&A---------------$6.85M$8.57M$8.09M$8.37M$7.04M$7.45M$6.84M$5.44M$4.49M$4.13M$3.46M$2.61M$3.52M$2.70M$2.79M
Avg Forecast$161.20K$161.47K$161.74K$162.00K$386.04K$386.04K$386.04K$386.04K$1.74M$1.78M$1.23M$488.01K$1.76M$2.05M$4.95M$6.56M$7.36M$6.70M$9.39M$10.97M$9.56M$10.21M$9.59M$9.08M$17.69M$9.36M$5.54M$3.52M$3.29M$3.94M
High Forecast$161.20K$161.47K$161.74K$162.00K$386.04K$386.04K$386.04K$386.04K$1.74M$2.84M$1.23M$488.01K$2.79M$2.05M$4.95M$6.56M$7.36M$6.70M$9.39M$10.97M$9.56M$10.21M$9.59M$10.90M$17.69M$9.36M$5.54M$4.23M$3.29M$3.94M
Low Forecast$161.20K$161.47K$161.74K$162.00K$386.04K$386.04K$386.04K$386.04K$1.74M$705.88K$1.23M$488.01K$684.36K$2.05M$4.95M$6.56M$7.36M$6.70M$9.39M$10.97M$9.56M$10.21M$9.59M$7.27M$17.69M$9.36M$5.54M$2.82M$3.29M$3.94M
Surprise %---------------1.04%1.16%1.21%0.89%0.64%0.78%0.67%0.57%0.49%0.23%0.37%0.47%1.00%0.82%0.71%

Affimed's average Quarter SG&A projection for Jun 23 is $4.95M, based on 2 Wall Street analysts, with a range of $4.95M to $4.95M. The forecast indicates a -27.71% fall compared to AFMD last annual SG&A of $6.85M (Mar 23).

Affimed EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts111111112322522211112222118812712
EPS---------------$-0.21$-0.26$-0.09$-0.12$-0.14$-0.29$-0.14$-0.16$0.01$-0.13$-0.07$-0.16$-0.11$-0.17$-0.17
Avg Forecast$-0.95$-0.96$-0.83$-0.83$-0.72$-0.62$-0.53$-0.57$-0.69$-0.92$-0.97$-1.55$-1.55$-1.85$-1.87$-1.91$-1.90$-1.74$-1.67$-1.76$-1.60$-1.40$-0.86$-1.00$-0.15$-0.82$-1.32$-1.29$-1.79$-1.79
High Forecast$-0.95$-0.96$-0.83$-0.83$-0.72$-0.62$-0.53$-0.57$-0.69$-0.90$-0.97$-1.55$-1.17$-1.85$-1.87$-1.91$-1.90$-1.74$-1.67$-1.76$-1.60$-1.40$-0.86$-1.00$-0.15$-0.82$-1.32$-1.29$-1.79$-1.79
Low Forecast$-0.95$-0.96$-0.83$-0.83$-0.72$-0.62$-0.53$-0.57$-0.69$-0.96$-0.97$-1.55$-2.00$-1.85$-1.87$-1.91$-1.90$-1.74$-1.67$-1.76$-1.60$-1.40$-0.86$-1.00$-0.15$-0.82$-1.32$-1.29$-1.79$-1.79
Surprise %---------------0.11%0.14%0.05%0.07%0.08%0.18%0.10%0.19%-0.01%0.86%0.09%0.12%0.09%0.10%0.09%

According to 2 Wall Street analysts, Affimed's projected average Quarter EPS for Jun 21 is $-0.86, with a low estimate of $-0.86 and a high estimate of $-0.86. This represents a -8665.40% decrease compared to AFMD previous annual EPS of $0.01 (Mar 21).

Affimed Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
HEPAHepion Pharmaceuticals$0.63$70.0011011.11%Buy
ELEVElevation Oncology$0.52$9.001630.77%Buy
XFORX4 Pharmaceuticals$0.53$3.67592.45%Buy
ADAPAdaptimmune Therapeutics$0.83$2.83240.96%Buy
INZYInozyme Pharma$4.42$14.67231.90%Buy
ADCTADC Therapeutics SA$3.02$9.33208.94%Buy
PDSBPDS Bio$3.23$9.00178.64%Buy
DAWNDay One Biopharmaceuticals$14.81$38.80161.99%Buy
AFMDAffimed$3.27$7.50129.36%Buy
TERNTerns Pharmaceuticals$7.10$14.25100.70%Buy
AGENAgenus$4.06$8.0097.04%Hold
MREOMereo BioPharma Group$4.01$6.7568.33%Buy
LPTXLeap Therapeutics$3.67$5.5049.86%Buy
CRVSCorvus Pharmaceuticals$9.02$9.505.32%Buy
EFTReFFECTOR Therapeutics-$5.50-Buy

AFMD Forecast FAQ


Yes, according to 5 Wall Street analysts, Affimed (AFMD) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of AFMD's total ratings.

Affimed (AFMD) average price target is $7.5 with a range of $5 to $10, implying a 129.36% from its last price of $3.27. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for AFMD stock, the company can go up by 129.36% (from the last price of $3.27 to the average price target of $7.5), up by 205.81% based on the highest stock price target, and up by 52.91% based on the lowest stock price target.

AFMD's average twelve months analyst stock price target of $7.5 supports the claim that Affimed can reach $5 in the near future.

Affimed's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.45M (high $1.45M, low $1.45M), average EBITDA is $-1.451M (high $-1.451M, low $-1.451M), average net income is $-37.339M (high $-37.339M, low $-37.339M), average SG&A $1.54M (high $1.54M, low $1.54M), and average EPS is $-2.44 (high $-2.44, low $-2.44). AFMD's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $607.42K (high $607.42K, low $607.42K), average EBITDA is $-607K (high $-607K, low $-607K), average net income is $-54.611M (high $-54.611M, low $-54.611M), average SG&A $646.41K (high $646.41K, low $646.41K), and average EPS is $-3.569 (high $-3.569, low $-3.569).

Based on Affimed's last annual report (Dec 2022), the company's revenue was $41.35M, beating the average analysts forecast of $32.35M by 27.84%. Apple's EBITDA was $-86.637M, beating the average prediction of $-32.346M by 167.84%. The company's net income was $-86.004M, missing the average estimation of $-108M by -20.50%. Apple's SG&A was $32.08M, missing the average forecast of $34.42M by -6.82%. Lastly, the company's EPS was $-0.6, missing the average prediction of $-7.07 by -91.51%. In terms of the last quarterly report (Mar 2023), Affimed's revenue was $4.51M, missing the average analysts' forecast of $6.16M by -26.82%. The company's EBITDA was $-30.662M, beating the average prediction of $-6.163M by 397.50%. Affimed's net income was $-31.983M, beating the average estimation of $-29.218M by 9.46%. The company's SG&A was $6.85M, beating the average forecast of $6.56M by 4.44%. Lastly, the company's EPS was $-0.21, missing the average prediction of $-1.91 by -89.00%